A clinical study in 2014 showed the liraglutide therapy-induced visfatin protein expression level in T2DM patients [75], and another report in 2016 indicated that higher levels of GLP-1 were associated with increased visfatin in maternal and cord blood of participants [76]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.